NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 25 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 12 words
- Enrollment increased: 297 → 397 participants
- Trial arms changed: 6 → 10
- Site details revised at 3 of 56 sites
- Minor Study sites: 55 to 56v24
Minor Enrollment increased: 220 → 297 participantsv23 Show 5 more changesShow less
- Primary and study completion moved earlier from Oct 30, 2028 to Jun 30, 2028
- Trial arms changed: 5 → 6
- Study sites: 54 to 55
- Interventions: Bevacizumab (Drug), Cemiplimab (Drug), Fianlimab (Drug), PLD (Drug), Sarilumab (Drug), Ubamatamab (Drug) to Bevacizumab (Drug), Cemiplimab (Drug), Fianlimab (Drug), PLD (Drug), REGN10597 (Drug), Sarilumab (Drug), Ubamatamab (Drug)
- Secondary endpoints: 16 to 19
- Minor Study sites: 53 to 54v22
- Minor Study sites: 52 to 53v21
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 50 to 52v20
- Minor Site details revised at 1 of 50 sitesv19
- Minor Trial sites expanded: 47 → 50 locationsv18
- Notable Eligibility criteria expanded, about 22 words
- Study sites: 44 to 47
- Primary and study completion dates: Dec 7, 2028 to Oct 30, 2028
- Secondary endpoints revised (16)
- Minor Study sites: 43 to 44v16
- Minor Study sites: 41 to 43v15
- Minor Study sites: 36 to 41v14
- Minor Study sites: 34 to 36v13
- Minor Study sites: 30 to 34v12
- Minor Study sites: 29 to 30v11
- Minor Study sites: 24 to 29v10
- Minor Study sites: 22 to 24v9
- Minor Study sites: 19 to 22v8
- Minor Study sites: 16 to 19v7
- Minor Study sites: 9 to 16v6
- Minor Study sites: 6 to 9v5
- Minor Study sites: 1 to 6v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of May 23, 2025 to May 28, 2025
- Notable Primary and study completion dates: Apr 30, 2028 to Dec 7, 2028
- Start date: May 1, 2025 to May 23, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
Timeframe: Up to 3 years
Secondary (19)
Cancer Antigen (CA) -125 response by Gynecologic Cancer Intergroup (GCIG) Criteria
Complete Response (CR) rate by RECIST 1.1
Disease Control Rate (DCR) by RECIST 1.1
Duration of Response (DOR) by RECIST 1.1
Progression-Free Survival (PFS) by RECIST 1.1
Show 14 moreShow less
Occurrence of Grade ≥ 2 Cytokine Release Syndrome (CRS) by Lee criteria
Treatment-Emergent Adverse Events (TEAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
TEAEs by Lee criteria
Concentration of ubamatamab in serum
Concentration of fianlimab in serum
Concentration of REGN10597 in serum
Occurrence of Anti-Drug Antibodies (ADA) to ubamatamab
Magnitude of ADA to ubamatamab
Occurrence of ADA to fianlimab
Magnitude of ADA to fianlimab
Occurrence of ADA to cemiplimab
Magnitude of ADA to cemiplimab
Occurrence of ADA to REGN10597
Magnitude of ADA to REGN10597
Arms and interventions
Arm A1Experimental
Arm A2Experimental
Arm BExperimental
Arm CExperimental
Arm DExperimental
Arms E1/E2Experimental
Arm FaExperimental
Arm GaExperimental
Arm FbExperimental
Arm GbExperimental
Drugs: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
Sites
56 sites in 5 countries
United States 21, Turkey (Türkiye) 12, South Korea 10, Taiwan 7, Canada 6